DE69220287T2 - Bindungspeptiden - Google Patents

Bindungspeptiden

Info

Publication number
DE69220287T2
DE69220287T2 DE69220287T DE69220287T DE69220287T2 DE 69220287 T2 DE69220287 T2 DE 69220287T2 DE 69220287 T DE69220287 T DE 69220287T DE 69220287 T DE69220287 T DE 69220287T DE 69220287 T2 DE69220287 T2 DE 69220287T2
Authority
DE
Germany
Prior art keywords
phe
leu
val
seq
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69220287T
Other languages
English (en)
Other versions
DE69220287D1 (de
Inventor
Steven Paul Adams
Joseph Walter Bulock
Robert Joseph Fallon
David Hirsh Perlmutter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of DE69220287D1 publication Critical patent/DE69220287D1/de
Publication of DE69220287T2 publication Critical patent/DE69220287T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69220287T 1991-04-24 1992-04-23 Bindungspeptiden Expired - Fee Related DE69220287T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/690,284 US5175253A (en) 1991-04-24 1991-04-24 Binding peptides

Publications (2)

Publication Number Publication Date
DE69220287D1 DE69220287D1 (de) 1997-07-17
DE69220287T2 true DE69220287T2 (de) 1998-01-08

Family

ID=24771856

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69220287T Expired - Fee Related DE69220287T2 (de) 1991-04-24 1992-04-23 Bindungspeptiden

Country Status (9)

Country Link
US (1) US5175253A (de)
EP (1) EP0511188B1 (de)
JP (1) JP3418415B2 (de)
AT (1) ATE154361T1 (de)
CA (1) CA2066913C (de)
DE (1) DE69220287T2 (de)
DK (1) DK0511188T3 (de)
ES (1) ES2103921T3 (de)
GR (1) GR3024516T3 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5792749A (en) * 1997-01-09 1998-08-11 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
CA2390652C (en) 1999-11-08 2011-03-29 Ipf Pharmaceuticals Gmbh Human circulating virus-inhibiting peptide (virip) and its use
FR2808024B1 (fr) * 2000-04-21 2006-09-15 Bio Merieux Complexe electroactif, sonde electroactive et procede de preparation
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US20050175195A1 (en) * 2004-02-10 2005-08-11 Cheney Maynard C.Jr. Detecting connectivity of a speaker
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
EP1909810B2 (de) 2005-06-07 2017-08-23 The Regents of the University of Colorado Hemmer der serinprotease-aktivität und ihre verwendung in verfahren und zusammensetzungen zur behandlung von transplantat-abstossung und förderung des transplantat-überlebens
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
JP5309210B2 (ja) 2008-04-29 2013-10-09 カーディアック ペースメイカーズ， インコーポレイテッド 脊髄刺激を送達する刺激送達システム
US9522179B2 (en) * 2010-03-04 2016-12-20 Virginia Commonwealth University Compositions and methods for modulating cardiac conditions
WO2011127624A1 (zh) * 2010-04-13 2011-10-20 中国人民解放军军事医学科学院毒物药物研究所 抗hiv肽
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用

Also Published As

Publication number Publication date
DK0511188T3 (da) 1997-10-27
ATE154361T1 (de) 1997-06-15
US5175253A (en) 1992-12-29
ES2103921T3 (es) 1997-10-01
GR3024516T3 (en) 1997-11-28
EP0511188A2 (de) 1992-10-28
JPH05271275A (ja) 1993-10-19
CA2066913C (en) 2002-11-26
EP0511188B1 (de) 1997-06-11
JP3418415B2 (ja) 2003-06-23
DE69220287D1 (de) 1997-07-17
EP0511188A3 (en) 1993-01-27
CA2066913A1 (en) 1992-10-25

Similar Documents

Publication Publication Date Title
ATE154361T1 (de) Bindungspeptiden
Carlsen et al. Human chorionic gonadotropin: linear amino acid sequence of the β subunit
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
EP2327775A3 (de) Herstellung von menschlichen alpha-Galactosidase A
PT82132A (en) Process to determine sequences of amino acids of polypeptides complementary polypeptides or proteins which have a sequence o f amino acids or a coded sequence of nucleotides at least part ially known
ES2184728T3 (es) Proteinas de union a la fibronectina.
ATE138102T1 (de) Verfahren zur herstellung von cysteinfreien peptiden
DE175360T1 (de) Antikoerper gegen petide und ihre verwendung zum nachweis von onkogene-produkten.
Ling Solid phase synthesis of porcine α-endorphin and γ-endorphin, two hypothalamic-pituitary peptides with opiate activity
US5422426A (en) Rapid synthesis and screening of peptide mimetics
NZ333606A (en) Isolated peptides derived from MAGE-2
RU93045577A (ru) Слитные полипептиды
KR100295606B1 (de)
Sletten et al. The primary structure of equine serum amyloid A (SAA) protein
ES2095255T3 (es) Analogos de sustitucion de peptidos magainina.
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
Cox et al. Incorporation of trans-olefinic dipeptide isosteres into enkephalin and substance P analogues
JPS6470498A (en) Synthetic peptide and antibody thereto
Schuppan et al. Sequence comparison of pepsin-resistant segments of basement-membrane collagen α 1 (IV) chains from bovine lens capsule and mouse tumour
AU3825389A (en) Hcg peptides for use in antibody purification procedures
Shinoda et al. Amino Acid Sequence of Human λ Chains: I. TRYPTIC PEPTIDES OF PROTEIN Ha
Kiso et al. Neo‐kyotorphin (Thr—Ser—Lys—Tyr—Arg), a new analgesic peptide
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
Timpl et al. Disulfide-linked cyanogen bromide peptides of bovine fibrinogen II. Isolation and sequence analysis of the chain constituents from the amino terminal region

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee